Objective: To study the efficacy of Cinobufagin capsule combined with hydroxycamptothecin in the treatment of patients with advanced esophageal cancer. Methods: 120 patients with esophageal cancer in our hospital from January 2015 to May 2017 were selected as the study subjects. All patients were divided into control group and treatment group according to the treatment plan, 60 cases in each. The patients in the control group were given hydroxycamptothecin, on top of which, the treatment group was given Cinobufagin capsule daily. The objective remission rate, clinical benefit rate, pain degree, quality of life and side effects were compared between the two groups. The level of tumor markers and 1-year survival rate of the two groups were compared before and after treatment. Results: After treatment, the clinical benefit rate, objective remission rate and quality of life of the treatment group were significantly higher than those of the control group. The pain degree of the treatment group was significantly lighter than that of the control group, and the difference was statistically significant (P<0.05); after treatment, the two groups of patients with CEA, CA19-9 and CA72-4 were significantly better than those before the treatment. The level of tumor markers in the treatment group was significantly better than that in the control group (P<0.05), and there was no significant difference in the 1 year survival rate and the side effects in the two groups (P>0.05). Conclusion: Cinobufagin capsule combined with hydroxycamptothecin has good clinical efficacy in the treatment of patients with advanced esophageal cancer. It can effectively improve the quality of life and the rate of clinical benefit, improve the level of tumor markers, reduce the degree of cancer pain and have high safety, which is worthy of clinical promotion.
 XIA J,INAGAKI Y,GAO J,et al.Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas- and mitochondria-mediated pathways[J].Am J Chin Med,2017,45(7):1537-1556.
 EDGE S B,COMPTON C C.The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471-1474.
 FRIENDLER A H,ETTINGER R L.Karnofsky performance status scale[J].Spec Care Dentist,2010,29(4):147-148.
 WATANABE H,OKADA M,KAJI Y,et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.